Drug Profile
Research programme: allergic rhinitis vaccine - AFFiRiS
Latest Information Update: 28 Feb 2020
Price :
$50
*
At a glance
- Originator AFFiRiS
- Class Allergy immunotherapies; Antiallergics; Peptide vaccines
- Mechanism of Action Immunoglobulin E modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Allergic rhinitis
Most Recent Events
- 28 Feb 2020 No recent reports of development identified for preclinical development in Allergic-rhinitis in Austria
- 18 Jan 2016 Preclinical trials in Allergic rhinitis in Austria (unspecified route)